SP-111 | CAS#55602-38-5 | biochemical

MedKoo Cat#: 146010 | Name: SP-111

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SP-111 is an investigational drug being studied for its potential as an oral treatment for dry eye disease (DED). It is a novel mucolytic agent that works by breaking down mucus in the eyes, improving the quality of tears and enhancing tear film stability. SP-111 acts by targeting and modulating the viscoelastic properties of the tear film, reducing the symptoms of dryness and irritation associated with DED.

Chemical Structure

SP-111

CAS#55602-38-5

Theoretical Analysis

MedKoo Cat#: 146010

Name: SP-111

CAS#: 55602-38-5

Chemical Formula: C29H43NO4

Exact Mass: 469.3200

Molecular Weight: 469.67

Elemental Analysis: C, 74.16; H, 9.23; N, 2.98; O, 13.63

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

SP-111; SP111; SP 111;

IUPAC/Chemical Name

(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-yl 4-morpholinobutanoate

InChi Key

HAQNKTBQOIAWDB-DNQXCXABSA-N

InChi Code

1S/C29H43NO4/c1-5-6-7-9-22-19-25(33-27(31)10-8-13-30-14-16-32-17-15-30)28-23-18-21(2)11-12-24(23)29(3,4)34-26(28)20-22/h18-20,23-24H,5-17H2,1-4H3/t23-,24-/m1/s1

SMILES Code

[H][C@@]12CCC(C)=C[C@@]1([H])C3=C(OC2(C)C)C=C(CCCCC)C=C3OC(=O)CCCN4CCOCC4

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 469.67 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Shiang AL, Palka JK, Balasubramanian S, Figenshau RS, Smith ZL, Kim EH. Comparison of single-port and multi-port Retzius-sparing robot-assisted laparoscopic prostatectomy. J Robot Surg. 2023 Jun;17(3):835-840. doi: 10.1007/s11701-022-01464-z. Epub 2022 Oct 31. PMID: 36316538; PMCID: PMC9628306. 2: Järbe TU, McMillan DE. delta 9-THC as a discriminative stimulus in rats and pigeons: generalization to THC metabolites and SP-111. Psychopharmacology (Berl). 1980;71(3):281-9. doi: 10.1007/BF00433063. PMID: 6256796. 3: Segal M. The effects of SP-111, a water-soluble THC derivative, on neuronal activity in the rat brain. Brain Res. 1978 Jan 13;139(2):263-75. doi: 10.1016/0006-8993(78)90928-9. PMID: 624059. 4: Pennell C, Gupta J, March M, Arthur LG, Lindholm E, Herman M, Grewal H. A Standardized Protocol for Cervical Spine Evaluation in Children Reduces Imaging Utilization: A Pilot Study of the Pediatric Cervical Spine Clearance Working Group Protocol. J Pediatr Orthop. 2020 Sep;40(8):e780-e784. doi: 10.1097/BPO.0000000000001619. PMID: 32604349. 5: Quintão-Júnior JF, Natali AJ, Carneiro-Júnior MA, Castro CA, Drummond LR, Lavorato VN, Felix LB, Cruz Jdos S, Prímola-Gomes TN. Morphology and contractility in cardiomyocytes of rats with low exercise performance. Arq Bras Cardiol. 2012 May;98(5):431-6. English, Portuguese. doi: 10.1590/s0066-782x2012005000036. Epub 2012 Apr 12. PMID: 22499334. 6: Chen S, Gao R, Xiang X, Yang H, Ma H, Zheng T, Xiao Y, Zhang X, Li H, Fan G, Yu Y. Straw mulching and nitrogen application altered ammonia oxidizers communities and improved soil quality in the alkaline purple soil of southwest China. AMB Express. 2021 Apr 7;11(1):52. doi: 10.1186/s13568-021-01211-x. PMID: 33825988; PMCID: PMC8026789. 7: Seo AN, Park TI, Jin Y, Sun PL, Kim H, Chang H, Chung JH. Novel EGFR mutation-specific antibodies for lung adenocarcinoma: highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry. Lung Cancer. 2014 Mar;83(3):316-23. doi: 10.1016/j.lungcan.2013.12.008. Epub 2013 Dec 24. PMID: 24412618. 8: Hershkowitz M, Szechtman H. Pretreatment with delta 1-tetrahydrocannabinol and psychoactive drugs: effects on uptake of biogenic amines and on behavior. Eur J Pharmacol. 1979 Nov 16;59(3-4):267-76. doi: 10.1016/0014-2999(79)90290-5. PMID: 230975. 9: Sung SC, Jakubovic A. Interaction of a water-soluble derivative of delta-9-tetrahydrocannabinol with [3H]diazepam and [3H]flunitrazepam binding to rat brain membranes. Prog Neuropsychopharmacol Biol Psychiatry. 1987;11(2-3):335-40. doi: 10.1016/0278-5846(87)90078-9. PMID: 2819954. 10: Dykstra LA, McMillan DE, Harris LS. Effects of delta-9-THC and a water soluble ester of delta-9-THC on schedule-controlled behavior. Pharmacol Biochem Behav. 1975 Jan-Feb;3(1):29-32. doi: 10.1016/0091-3057(75)90077-5. PMID: 1129353. 11: Nicolau M, Lapa AJ, Valle JR. The inhibitory effect induced by delta9-tetrahydrocannabinol on the contractions of the isolated rat vas deferens. Arch Int Pharmacodyn Ther. 1978 Nov;236(1):131-6. PMID: 747459.